# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN
- Date: 2026-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week review, seen the same day by addiction medicine. **S**

## History of present illness

Ms. Garland returns one week after intake and is seen by Dr. Grünewald of addiction medicine on the same day. She has taken secobarbital 200 mg at bedtime from the seven-day supply on six nights; on one night before a recording session she took a third capsule when she could not sleep, and she told us so herself. She has had no daytime shakes, sweats, or seizure-like episodes. She has taken dextroamphetamine 10 mg each morning and no extra doses, and she has felt flat and tired in the afternoons. She has taken sertraline 25 mg daily without nausea or headache. She brought 38 unused secobarbital capsules and 22 dextroamphetamine tablets from earlier prescriptions, which she placed in the pharmacy take-back box with the nurse today. She keeps this week's supply in a locked box. She has two weeks free of performances from next week and would like to use them for the change. **S**

| Element | Detail |
|---|---|
| Secobarbital | 200 mg at bedtime on six nights; 300 mg on one night |
| Withdrawal symptoms | None |
| Dextroamphetamine | 10 mg each morning; no extra doses |
| Sertraline | 25 mg daily for a week; no side effects |
| Take-back | 38 secobarbital capsules and 22 dextroamphetamine tablets returned today |
| Work | Two weeks without performances from next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; no fever |
| Neurological | Negative | No tremor, unsteadiness or seizure-like episodes |
| Psychiatric | Positive | Low mood and worry, a little better; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine **S**
- Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy **S**
- Sertraline 50 mg oral tablet, one tablet daily **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/80 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 46.8 kg; BMI 20.5 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert; blood pressure 124/80, pulse 92 |
| Neurological | No tremor; no nystagmus; gait steady |
| Psychiatric | Engaged and candid; no signs of intoxication or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Barbiturate use disorder with physiological dependence** (F13.20). Daily secobarbital 200 to 300 mg for years means a high risk of seizures and delirium if it is stopped or cut quickly. Dr. Grünewald agrees that the change should be made in hospital: a planned four-day admission to the addiction medicine service to change to phenobarbital, a long-acting barbiturate, and find the dose that keeps her free of withdrawal, then a slow outpatient taper. Safety reviewed: no thoughts of suicide or self-harm; the unused capsules are gone and the supply is locked away. **S**
   - Admission planned for one week from today.
   - Continue secobarbital 200 mg at bedtime until admission, seven days at a time; no alcohol.
2. **Stimulant use disorder (prescribed amphetamine), mild** (F15.10). No extra doses this week. Stopping the stimulant can bring tiredness and low mood for a few weeks, so it will be tapered once phenobarbital is stable, not at the same time as the barbiturate change. **S**
   - Continue dextroamphetamine 10 mg each morning until the four-week visit.
3. **Depression with anxious distress** (F32.1). Sertraline 25 mg tolerated for a week. **S**
   - Increase sertraline to 50 mg daily.
   - Weekly psychotherapy, which she began this week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | 200 mg on six nights and 300 mg on one; no withdrawal signs |
| Referral | Setting for barbiturate withdrawal | Before any reduction | Ordered | Four-day admission to the addiction medicine service planned for next week, as advised today |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions since intake |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Up to date | At intake: barbiturates and amphetamine only; no opioids, fentanyl or benzodiazepines |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Seven-day supply; locked box; 38 capsules and 22 tablets taken back today |
| Medication safety | Stimulant dose, extra doses, cravings, and blood pressure and pulse | Every visit | Completed today | 10 mg each morning, no extra doses; blood pressure 124/80, pulse 92 |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | First CBT-I session booked; sleep diary started; Insomnia Severity Index 21 (moderate) |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic during the barbiturate taper |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Up to date | PHQ-9 14 a week ago; next at the four-week visit |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | No side effects on 25 mg; increased to 50 mg |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; unused capsules returned; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Psychotherapy | Weekly | Completed today | First session this week |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 46.8 kg; eating one or two meals a day |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used; naloxone would not reverse a barbiturate |
| Referral | Addiction medicine consultation | At the start of treatment | Completed today | Seen by Dr. Grünewald today |

## Goal progress

- Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium. In progress; target 2026-07-20. **S**
- Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping. In progress; target 2026-10-26. **S**
- Stop dextroamphetamine with a short taper and no return to it. In progress; target 2026-08-31. **S**
- Sleep six hours or more on most nights using CBT for insomnia. In progress; target 2026-10-26. **S**
- PHQ-9 below 5 by six months. In progress; target 2026-10-26. **S**
- Regular meals and weight she is comfortable with, without dieting drugs. In progress; target 2026-10-26. **S**

## Medication changes

- Stopped: Sertraline 25 mg oral tablet, one tablet daily **S**
- Started: Sertraline 50 mg oral tablet, one tablet daily **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Hospital admission in one week. Four-week review after discharge. Weekly psychotherapy and CBT-I. **S**
- Next scheduled visit 2026-07-20: four-week review eleven days after a supervised hospital change from secobarbital to phenobarbital: starting the outpatient taper and the stimulant taper. **S**
